HPV Vaccination Recommendation Practices among Adolescent Health Care Providers in 5 Countries - 02/11/18
Abstract |
Study Objective |
To assess adolescent health care providers’ recommendations for, and attitudes towards human papillomavirus (HPV) vaccination in 5 countries.
Design |
In-depth interviews of adolescent health care providers, 2013-2014.
Setting |
Five countries where HPV vaccination is at various stages of implementation into national programs: Argentina, Malaysia, South Africa, South Korea, and Spain.
Participants |
Adolescent health care providers (N = 151) who had administered or overseen provision of adolescent vaccinations (N = Argentina: 30, Malaysia: 30, South Africa: 31, South Korea: 30, Spain: 30).
Main Outcome Measures |
Frequency of HPV vaccination recommendation, reasons providers do not always recommend the vaccine and facilitators to doing so, comfort level with recommending the vaccine, reasons for any discomfort, and positive and negative aspects of HPV vaccination.
Results |
Over half of providers 82/151 (54%) recommend HPV vaccination always or most of the time (range: 20% in Malaysia to 90% in Argentina). Most providers 112/151 (74%) said they were comfortable recommending HPV vaccination, although South Korea was an outlier 10/30 (33%). Providers cited protection against cervical cancer 124/151 (83%) and genital warts 56/151 (37%) as benefits of HPV vaccination. When asked about the problems with HPV vaccination, providers mentioned high cost 75/151 (50% overall; range: 26% in South Africa to 77% in South Korea) and vaccination safety 28/151 (19%; range: 7% in South Africa to 33% in Spain). Free, low-cost, or publicly available vaccination 59/151 (39%), and additional data on vaccination safety 52/151 (34%) and efficacy 43/151 (28%) were the most commonly cited facilitators of health provider vaccination recommendation.
Conclusion |
Interventions to increase HPV vaccination should consider a country's specific provider concerns, such as reducing cost and providing information on vaccination safety and efficacy.
Le texte complet de cet article est disponible en PDF.Key Words : Human papilloma virus, HPV-associated cancers, Cervical cancer, Vaccination, Health care provider recommendation
Plan
| Karin L. Richter has received research grants, received travel grants, and/or been a paid speaker for the GlaxoSmithKline (GSK) group of companies and Merck & Co, Inc over the past 5 years. Jennifer S. Smith has received research grants, served on paid advisory boards, and/or been a paid speaker for the GSK group of companies and Merck & Co, Inc over the past 5 years. The remaining authors indicate no conflicts of interest. |
|
| Hillary M. Topazian and Debanjali Kundu contributed equally to this work. |
|
| Present address for Kathryn Peebles: Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington. |
Vol 31 - N° 6
P. 575 - décembre 2018 Retour au numéro
Article précédent
- Prevalence of Female Circumcision among Young Women in Beni-Suef, Egypt: A Cross-Sectional Study
- Hamada Ashry Abd El Wahed Ali, Ahmed Emadeldin Arafa, Nesreen Abd El Fattah Abd Allah Shehata, Ashraf Samir Fahim
- Human Papillomavirus Vaccine Acceptability among Parents of Adolescent Girls in a Rural Area, Mysore, India
- Abraham Degarege, Karl Krupp, Kristopher Fennie, Vijaya Srinivas, Tan Li, Dionne P. Stephens, Laura A.V. Marlow, Anjali Arun, Purnima Madhivanan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?